At SEDOR PHARMACEUTICALS our top three programs are described below:

  • IM/IV CE Meloxicam for patients with acute pain, potentially delaying the use of opioids with associated risk of addiction
  • IM/IV CE Fosphenytoin to benefit patients with seizures, expanding the market to room-temperature access in all setting
  • IN CE Budesonide + Azelastine fixed-dose combination to improve convenience and outcomes for patients with allergic rhinitis